Warning of kidney failure issued for bowel cleansers
The FDA has issued an alert to both healthcare workers andconsumers following 21 reports of a type of renal failure known asacute phosphate nephropathy. The problems occurred following use ofthese oral sodium phosphate (OSP) products for bowel cleansingprior to a colonoscopy: Fleet Phospho-soda, Fleet Accu-Prep, andVisicol.
Warning of kidney failure issued for bowel cleansers
The FDA has issued an alert to both healthcare workers and consumers following 21 reports of a type of renal failure known as acute phosphate nephropathy. The problems occurred following use of these oral sodium phosphate (OSP) products for bowel cleansing prior to a colonoscopy: Fleet Phospho-soda, Fleet Accu-Prep, and Visicol. No cases have been reported for newly approved OsmoPrep. The renal impairment caused by the nephropathy is often permanent, warns the agency, possibly requiring chronic dialysis. Individuals at risk include dehydrated patients, the elderly, those with existing kidney disease, and those taking medications that can affect renal function, such as diuretics, ACE inhibitors, ARBs, and NSAIDs. Among the warnings, patients are advised to take the appropriate dose of OSP, drink plenty of clear fluids during bowel cleansing, and avoid concomitant use of laxatives.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
How Differences in Bispecific Therapies Impact Myeloma Treatment Operations
April 18th 2024According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.
